Seminars in Nuclear Medicine
Volume 34, Issue 4 , Pages 274-292 , October 2004

Positron emission tomography for prostate, bladder, and renal cancer

  • Heiko Schöder, MD

      Affiliations

    • Department of Radiology/Nuclear Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
    • Corresponding Author InformationAddress reprint requests to: Heiko Schöder, MD, Department of Radiology/Nuclear Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021.
    • ,
  • Steven M. Larson, MD

      Affiliations

    • Department of Radiology/Nuclear Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.

References 

  1. Jemal A , Tiwari RC , Murray T , et al.   Cancer statistics, 2004 . CA Cancer J Clin . 2004;54:8–29
  2. Craft N , Chhor C , Tran C , et al.   Evidence for clonal outgrowth of androgen-independent prostate cancer cells from androgen-dependent tumors through a two-step process . Cancer Res . 1999;59:5030–5036
  3. Chen CD , Welsbie DS , Tran C , et al.   Molecular determinants of resistance to antiandrogen therapy . Nat Med . 2004;10:33–39
  4. Scher HI , Heller G . Clinical states in prostate cancer (toward a dynamic model of disease progression) . Urology . 2000;55:323–327
  5. Partin AW , Kattan MW , Subong EN , et al.   Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update . JAMA . 1997;277:1445–1451
  6. Blute ML , Bergstralh EJ , Partin AW , et al.   Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer . J Urol . 2000;164:1591–1595
  7. Graefen M , Karakiewicz PI , Cagiannos I , et al.   A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men . Urol Oncol . 2002;7:141–146
  8. Gleason D . Histological grading and clinical staging of prostatic carcinoma (The Prostate) . In:  Tannenbaum T editors. Urologic Pathology . Philadelphia, PA: Lea & Febiger; 1977;p. 171–197
  9. Kattan MW , Wheeler TM , Scardino PT . Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer . J Clin Oncol . 1999;17:1499–1507
  10. DʼAmico AV , Whittington R , Schnall M , et al.   The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic cancer . Cancer . 1995;75:2368–2372
  11. Kattan MW , Eastham JA , Stapleton AM , et al.   A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer . J Natl Cancer Inst . 1998;90:766–771
  12. Rifkin MD , Zerhouni EA , Gatsonis CA , et al.   Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial . N Engl J Med . 1990;323:621–626
  13. Smith JA , Scardino PT , Resnick MI , et al.   Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate (results of a prospective, multi-institutional trial) . J Urol . 1997;157:902–906
  14. Hricak H , Dooms GC , Jeffrey RB , et al.   Prostatic carcinoma (staging by clinical assessment, CT, and MR imaging) . Radiology . 1987;162:331–336
  15. Yu KK , Hricak H . Imaging prostate cancer . Radiol Clin North Am . 2000;38:59–85
  16. Yu KK , Hricak H , Alagappan R , et al.   Detection of extracapsular extension of prostate carcinoma with endorectal and phased-array coil MR imaging (multivariate feature analysis) . Radiology . 1997;202:697–702
  17. Bartolozzi C , Menchi I , Lencioni R , et al.   Local staging of prostate carcinoma with endorectal coil MRI (correlation with whole-mount radical prostatectomy specimens) . Eur Radiol . 1996;6:339–345
  18. Tempany CM , Zhou X , Zerhouni EA , et al.   Staging of prostate cancer (results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques) . Radiology . 1994;192:47–54
  19. Kurhanewicz J , Vigneron DB , Nelson SJ . Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer . Neoplasia . 2000;2:166–189
  20. Yu KK , Scheidler J , Hricak H , et al.   Prostate cancer (prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging) . Radiology . 1999;213:481–488
  21. Warburg O . Metabolism of Tumors . New York, NY: Richard R. Smith; 1931;
  22. Singh G , Lakkis CL , Laucirica R , et al.   Regulation of prostate cancer cell division by glucose . J Cell Physiol . 1999;180:431–438
  23. Rossi F , Grzeskowiak M , Della Bianca V , et al.   De novo synthesis of diacylglycerol from glucose . A new pathway of signal transduction in human neutrophils stimulated during phagocytosis of beta-glucan particles. J Biol Chem . 1991;266:8034–8038
  24. Agus DB , Golde DW , Sgouros G , et al.   Positron emission tomography of a human prostate cancer xenograft (association of changes in deoxyglucose accumulation with other measures of outcome following androgen withdrawal) . Cancer Res . 1998;58:3009–3014
  25. Seltzer MA , Barbaric Z , Belldegrun A , et al.   Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer . J Urol . 1999;162:1322–1328
  26. Oyama N , Akino H , Kanamaru H , et al.   11C-acetate PET imaging of prostate cancer . J Nucl Med . 2002;43:181–186
  27. Herrmann K , Schöder H , Eberhard S , et al.   FDG PET for the detection of recurrent/metastatic prostate carcinoma in patients with rising PSA after radical prostatectomy . J Nucl Med . 2004;45:359; (abstr)
  28. Hofer C , Laubenbacher C , Block T , et al.   Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy . Eur Urol . 1999;36:31–35
  29. Effert PJ , Bares R , Handt S , et al.   Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose . J Urol . 1996;155:994–998
  30. Shreve PD , Grossman HB , Gross MD , et al.   Metastatic prostate cancer (initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose) . Radiology . 1996;199:751–756
  31. Fricke E , Machtens S , Hofmann M , et al.   Positron emission tomography with (11)C-acetate and (18)F-FDG in prostate cancer patients . Eur J Nucl Med Mol Imaging . 2003;30:607–611
  32. Larson SM , Morris M , Gunther I , et al.   Tumor localization of 16beta-(18)F-fluoro-5alpha-dihydrotestosterone versus (18)F-FDG in patients with progressive, metastatic prostate cancer . J Nucl Med . 2004;45:366–373
  33. Morris MJ , Akhurst T , Osman I , et al.   Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer . Urology . 2002;59:913–918
  34. Nunez R , Macapinlac HA , Yeung HW , et al.   Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer . J Nucl Med . 2002;43:46–55
  35. Turlakow A , Larson SM , Coakley F , et al.   Local detection of prostate cancer by positron emission tomography with 2-fluorodeoxyglucose (comparison of filtered back projection and iterative reconstruction with segmented attenuation correction) . Q J Nucl Med . 2001;45:235–244
  36. Shreve PD , Gross MD . Imaging of the pancreas and related diseases with PET carbon-11-acetate . J Nucl Med . 1997;38:1305–1310
  37. Shreve P , Chiao PC , Humes HD , et al.   Carbon-11-acetate PET imaging in renal disease . J Nucl Med . 1995;36:1595–1601
  38. Oyama N , Miller TR , Dehdashti F , et al.   11C-Acetate PET Imaging of Prostate Cancer (Detection of Recurrent Disease at PSA Relapse) . J Nucl Med . 2003;44:549–555
  39. Kotzerke J , Volkmer BG , Neumaier B , et al.   Carbon-11 acetate positron emission tomography can detect local recurrence of prostate cancer . Eur J Nucl Med Mol Imaging . 2002;29:1380–1384
  40. Ponde D , Oyama N , Dence C , et al.   18F fluoroacetate, an analogue on 11C acetate for tumor imaging . J Nucl Med . 2003;44:296; (abstr)
  41. Matthies A , Ezziddin S , Ulrich EM , et al.   Imaging of prostate cancer metastases with (18)F-fluoroacetate using PET/CT . Eur J Nucl Med Mol Imaging . 2004;31:797
  42. Yoshimoto M , Waki A , Yonekura Y , et al.   Characterization of acetate metabolism in tumor cells in relation to cell proliferation (acetate metabolism in tumor cells) . Nucl Med Biol . 2001;28:117–122
  43. Swinnen JV , Van Veldhoven PP , Timmermans L , et al.   Fatty acid synthase drives the synthesis of phospholipids partitioning into detergent-resistant membrane microdomains . Biochem Biophys Res Commun . 2003;302:898–903
  44. Armbrecht JJ , Buxton DB , Schelbert HR . Validation of [1-11C]acetate as a tracer for noninvasive assessment of oxidative metabolism with positron emission tomography in normal, ischemic, postischemic, and hyperemic canine myocardium . Circulation . 1990;81:1594–1605
  45. Armbrecht JJ , Buxton DB , Brunken RC , et al.   Regional myocardial oxygen consumption determined noninvasively in humans with [1-11C]acetate and dynamic positron tomography . Circulation . 1989;80:863–872
  46. Buxton DB , Nienaber CA , Luxen A , et al.   Noninvasive quantitation of regional myocardial oxygen consumption in vivo with [1-11C]acetate and dynamic positron emission tomography . Circulation . 1989;79:134–142
  47. Costello LC , Franklin RB . The intermediary metabolism of the prostate (a key to understanding the pathogenesis and progression of prostate malignancy) . Oncology . 2000;59:269–282
  48. Costello LC , Liu Y , Franklin RB , et al.   Zinc inhibition of mitochondrial aconitase and its importance in citrate metabolism of prostate epithelial cells . J Biol Chem . 1997;272:28875–28881
  49. Swinnen JV , Verhoeven G . Androgens and the control of lipid metabolism in human prostate cancer cells . J Steroid Biochem Mol Biol . 1998;65:191–198
  50. Swinnen JV , Roskams T , Joniau S , et al.   Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer . Int J Cancer . 2002;98:19–22
  51. Simons K , Toomre D . Lipid rafts and signal transduction . Nat Rev Mol Cell Biol . 2000;1:31–39
  52. Rouquette-Jazdanian AK , Pelassy C , Breittmayer JP , et al.   Metabolic labeling of membrane microdomains/rafts in Jurkat cells indicates the presence of glycerophospholipids implicated in signal transduction by the CD3 T-cell receptor . Biochem J . 2002;363:645–655
  53. Kato T , Tsukamoto E , Kuge Y , et al.   Accumulation of [(11)C]acetate in normal prostate and benign prostatic hyperplasia (comparison with prostate cancer) . Eur J Nucl Med Mol Imaging . 2002;29:1492–1495
  54. Zeisel SH , Blusztajn JK . Choline and human nutrition . Annu Rev Nutr . 1994;14:269–296
  55. Ratnam S , Kent C . Early increase in choline kinase activity upon induction of the H-ras oncogene in mouse fibroblast cell lines . Arch Biochem Biophys . 1995;323:313–322
  56. Ackerstaff E , Pflug BR , Nelson JB , et al.   Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells . Cancer Res . 2001;61:3599–3603
  57. Katz-Brull R , Degani H . Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method . Anticancer Res . 1996;16:1375–1380
  58. Hara T , Kosaka N , Shinoura N , et al.   PET imaging of brain tumor with [methyl-11C]choline . J Nucl Med . 1997;38:842–847
  59. Hara T , Kosaka N , Kishi H . PET imaging of prostate cancer using carbon-11-choline . J Nucl Med . 1998;39:990–995
  60. Hara T , Inagaki K , Kosaka N , et al.   Sensitive detection of mediastinal lymph node metastasis of lung cancer with 11C-choline PET . J Nucl Med . 2000;41:1507–1513
  61. Kobori O , Kirihara Y , Kosaka N , et al.   Positron emission tomography of esophageal carcinoma using (11)C-choline and (18)F-fluorodeoxyglucose (a novel method of preoperative lymph node staging) . Cancer . 1999;86:1638–1648
  62. Price DT , Coleman RE , Liao RP , et al.   Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer . J Urol . 2002;168:273–280
  63. Picchio M , Messa C , Landoni C , et al.   Value of [11C]choline-positron emission tomography for re-staging prostate cancer (a comparison with [18F]fluorodeoxyglucose-positron emission tomography) . J Urol . 2003;169:1337–1340
  64. Kotzerke J , Prang J , Neumaier B , et al.   Experience with carbon-11 choline positron emission tomography in prostate carcinoma . Eur J Nucl Med . 2000;27:1415–1419
  65. de Jong IJ , Pruim J , Elsinga PH , et al.   Visualization of prostate cancer with 11C-choline positron emission tomography . Eur Urol . 2002;42:18–23
  66. de Jong IJ , Pruim J , Elsinga PH , et al.   Preoperative staging of pelvic lymph nodes in prostate cancer by (11)C-choline PET . J Nucl Med . 2003;44:331–335
  67. de Jong IJ , Pruim J , Elsinga PH , et al.   11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer . Eur Urol . 2003;44:32–38 discussion 38-39
  68. Roivainen A , Forsback S , Gronroos T , et al.   Blood metabolism of [methyl-11C]choline; implications for in vivo imaging with positron emission tomography . Eur J Nucl Med . 2000;27:25–32
  69. Hara T , Kosaka N , Kishi H . Development of (18)F-fluoroethylcholine for cancer imaging with PET (synthesis, biochemistry, and prostate cancer imaging) . J Nucl Med . 2002;43:187–199
  70. DeGrado TR , Coleman RE , Wang S , et al.   Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography (initial findings in prostate cancer) . Cancer Res . 2001;61:110–117
  71. DeGrado TR , Baldwin SW , Wang S , et al.   Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers . J Nucl Med . 2001;42:1805–1814
  72. DeGrado TR , Reiman RE , Price DT , et al.   Pharmacokinetics and radiation dosimetry of 18F-fluorocholine . J Nucl Med . 2002;43:92–96
  73. Sutinen E , Nurmi M , Roivainen A , et al.   Kinetics of [(11)C]choline uptake in prostate cancer (a PET study [correction for stydy]) . Eur J Nucl Med Mol Imaging . 2004;31:317–324
  74. Wyss MT , Weber B , Honer M , et al.   18F-choline in experimental soft tissue infection assessed with autoradiography and high-resolution PET . Eur J Nucl Med Mol Imaging . 2004;31:312–316
  75. Miyazawa H , Arai T , Iio M , et al.   PET imaging of non-small-cell lung carcinoma with carbon-11-methionine (relationship between radioactivity uptake and flow-cytometric parameters) . J Nucl Med . 1993;34:1886–1891
  76. Lindholm P , Leskinen S , Lapela M . Carbon-11-methionine uptake in squamous cell head and neck cancer . J Nucl Med . 1998;39:1393–1397
  77. Lindholm P , Leskinen S , Nagren K , et al.   Carbon-11-methionine PET imaging of malignant melanoma . J Nucl Med . 1995;36:1806–1810
  78. Ogawa T , Shishido F , Kanno I , et al.   Cerebral glioma (Evaluation with methionine PET) . Radiology . 1993;186:45–53
  79. Schober O , Duben C , Meyer G , et al.   Nonselective transport of [11C-methyl]-L- and D-methionine into a malignant glioma . Eur J Nucl Med . 1987;13:103–105
  80. Hatazawa J , Ishiwata K , Itoh M , et al.   Quantitative evaluation of L-[methyl]-11C methionine uptake in tumor using positron emission tomography . J Nucl Med . 1989;30:1809–1813
  81. Kubota R , Kubota K , Yamada S , et al.   Methionine uptake by tumor tissue (A microautoradiographic comparison with FDG) . J Nucl Med . 1995;36:484–492
  82. Nilsson S , Kalkner K , Ginman C , et al.   C-11 methionine positron emission tomography in the management of prostatic carcinoma . Antibody Immunconj Radiopharm . 1995;8:23
  83. Macapinlac HA , Humm JL , Akhurst T , et al.   Differential metabolism and pharmacokinetics of L-[1-(11)C]-methionine and 2-[(18)F] fluoro-2-deoxy-D-glucose (FDG) in androgen independent prostate cancer . Clin Positron Imaging . 1999;2:173–181
  84. Craft N , Sawyers CL . Mechanistic concepts in androgen-dependence of prostate cancer . Cancer Metastasis Rev . 1998;17:421–427
  85. Bonasera TA , OʼNeil JP , Xu M , et al.   Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons . J Nucl Med . 1996;37:1009–1015
  86. Chandler JD , Williams ED , Slavin JL , et al.   Expression and localization of GLUT1 and GLUT12 in prostate carcinoma . Cancer . 2003;97:2035–2042
  87. Liu IJ , Zafar MB , Lai YH , et al.   Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer . Urology . 2001;57:108–111
  88. Smith JA , Seaman JP , Gleidman JB , et al.   Pelvic lymph node metastasis from prostatic cancer (influence of tumor grade and stage in 452 consecutive patients) . J Urol . 1983;130:290–292
  89. Bundrick WS , Culkin DJ , Mata JA , et al.   Evaluation of the current incidence of nodal metastasis from prostate cancer . J Surg Oncol . 1993;52:269–271
  90. Danella JF , deKernion JB , Smith RB , et al.   The contemporary incidence of lymph node metastases in prostate cancer (implications for laparoscopic lymph node dissection) . J Urol . 1993;149:1488–1491
  91. Eastham J , Scardino P . In: Radical Prostatectomy, in Campbellʼs Urology . Philadelphia, PA: Saunders; 1998;p. 2547–2561
  92. Ohori M , Wheeler TM , Dunn JK , et al.   The pathological features and prognosis of prostate cancer detectable with current diagnostic tests . J Urol . 1994;152:1714–1720
  93. Bader P , Burkhard FC , Markwalder R , et al.   Is a limited lymph node dissection an adequate staging procedure for prostate cancer? . J Urol . 2002;168:514–518 discussion 518
  94. Heidenreich A , Varga Z , Von Knobloch R . Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy (high incidence of lymph node metastasis) . J Urol . 2002;167:1681–1686
  95. Edelstein RA , Zietman AL , de las Morenas A , et al.   Implications of prostate micrometastases in pelvic lymph nodes (An archival tissue study) . Urology . 1996;47:370–375
  96. Cheng L , Zincke H , Blute ML , et al.   Risk of prostate carcinoma death in patients with lymph node metastasis . Cancer . 2001;91:66–73
  97. Zincke H , Lau W , Bergstralh E , et al.   Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer . J Urol . 2001;166:2208–2215
  98. Graefen M , Karakiewicz PI , Cagiannos I , et al.   Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer . J Clin Oncol . 2002;20:951–956
  99. Cheng L , Bergstralh EJ , Cheville JC , et al.   Cancer volume of lymph node metastasis predicts progression in prostate cancer . Am J Surg Pathol . 1998;22:1491–1500
  100. Steinberg GD , Epstein JI , Piantadosi S , et al.   Management of stage D1 adenocarcinoma of the prostate (the Johns Hopkins experience 1974 to 1987) . J Urol . 1990;144:1425–1432
  101. Seay TM , Blute ML , Zincke H . Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation . J Urol . 1998;159:357–364
  102. Oyen R , van Poppel F , van de Voorde W , et al.   Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy (Prospective study of 285 patients) . Radiology . 1994;190:315–322
  103. Wolf JS , Cher M , Dallʼera M , et al.   The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy . J Urol . 1995;153:993–999
  104. Tiguert R , Gheiler EL , Tefilli MV , et al.   Lymph node size does not correlate with the presence of prostate cancer metastasis . Urology . 1999;53:367–371
  105. Flanigan RC , McKay TC , Olson M , et al.   Limited efficacy of preoperative computed tomographic scanning for the evaluation of lymph node metastasis in patients before radical prostatectomy . Urology . 1996;48:428–432
  106. Harisinghani MG , Barentsz J , Hahn PF , et al.   Noninvasive detection of clinically occult lymph-node metastases in prostate cancer . N Engl J Med . 2003;348:2491–2499
  107. Takashima H , Egawa M , Imao T , et al.   Validity of sentinel lymph node concept for patients with prostate cancer . J Urol . 2004;171:2268–2271
  108. Wawroschek F , Vogt H , Wengenmair H , et al.   Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases . Urol Int . 2003;70:303–310
  109. Chybowski FM , Keller JJ , Bergstralh EJ , et al.   Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer (prostate specific antigen is superior to all other clinical parameters) . J Urol . 1991;145:313–318
  110. Lee CT , Oesterling JE . Using prostate-specific antigen to eliminate the staging radionuclide bone scan . Urol Clin North Am . 1997;24:389–394
  111. Heicappell R , Muller-Mattheis V , Reinhardt M , et al.   Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-[(18)F]-2-deoxy-D-glucose . Eur Urol . 1999;36:582–587
  112. Yeh SD , Imbriaco M , Larson SM , et al.   Detection of bony metastases of androgen-independent prostate cancer by PET-FDG . Nucl Med Biol . 1996;23:693–697
  113. Even-Sapir E , Metser U , Flusser G , et al.   Assessment of malignant skeletal disease (initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT) . J Nucl Med . 2004;45:272–278
  114. Leventis AK , Shariat SF , Slawin KM . Local recurrence after radical prostatectomy (correlation of US features with prostatic fossa biopsy findings) . Radiology . 2001;219:432–439
  115. Fowler JE , Brooks J , Pandey P , et al.   Variable histology of anastomotic biopsies with detectable prostate specific antigen after radical prostatectomy . J Urol . 1995;153:1011–1014
  116. Connolly JA , Shinohara K , Presti JC , et al.   Local recurrence after radical prostatectomy (characteristics in size, location, and relationship to prostate-specific antigen and surgical margins) . Urology . 1996;47:225–231
  117. Albertsen PC , Hanley JA , Harlan LC , et al.   The positive yield of imaging studies in the evaluation of men with newly diagnosed prostate cancer (a population based analysis) . J Urol . 2000;163:1138–1143
  118. Johnstone P , GJ T , Riffenburgh RH . Yield of imaging and scintigraphy assessing biochemical failure in prostate cancer patients . Urol Oncol . 1997;3:108–112
  119. Kramer S , Gorich J , Gottfried HW , et al.   Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy . Br J Radiol . 1997;70:995–999
  120. Cox JD , Gallagher MJ , Hammond EH , et al.  American Society for Therapeutic Radiology and Oncology Consensus Panel   Consensus statements on radiation therapy of prostate cancer (guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy) . J Clin Oncol . 1999;17:1155
  121. Turner JW , Hawes DR , Williams RD . Magnetic resonance imaging for detection of prostate cancer metastatic to bone . J Urol . 1993;149:1482–1484
  122. Freedman GM , Negendank WG , Hudes GR , et al.   Preliminary results of a bone marrow magnetic resonance imaging protocol for patients with high-risk prostate cancer . Urology . 1999;54:118–123
  123. Sella T , Schwartz LH , Swindle PW , et al.   Suspected local recurrence after radical prostatectomy (endorectal coil MR imaging) . Radiology . 2004;231:379–385
  124. Silverman JM , Krebs TL . MR imaging evaluation with a transrectal surface coil of local recurrence of prostatic cancer in men who have undergone radical prostatectomy . Am J Roentgenol . 1997;168:379–385
  125. Ornstein DK , Colberg JW , Virgo KS , et al.   Evaluation and management of men whose radical prostatectomies failed (results of an international survey) . Urology . 1998;52:1047–1054
  126. Cher ML , Bianco FJ , Lam JS , et al.   Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy . J Urol . 1998;160:1387–1391
  127. Kane CJ , Amling CL , Johnstone PA , et al.   Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy . Urology . 2003;61:607–611
  128. Sabbatini P , Larson SM , Kremer A , et al.   Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer . J Clin Oncol . 1999;17:948–957
  129. Noguchi M , Kikuchi H , Ishibashi M , et al.   Percentage of the positive area of bone metastasis is an independent predictor of disease death in advanced prostate cancer . Br J Cancer . 2003;88:195–201
  130. Rigaud J , Tiguert R , Le Normand L , et al.   Prognostic value of bone scan in patients with metastatic prostate cancer treated initially with androgen deprivation therapy . J Urol . 2002;168:1423–1426
  131. Antoch G , Vogt FM , Freudenberg LS , et al.   Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology . JAMA . 2003;290:3199–3206
  132. Panel ASfTRaOC . Consensus Statements on Radiation Therapy of Prostate Cancer (Guidelines for Prostate Re-Biopsy After Radiation and for Radiation Therapy With Rising Prostate-Specific Antigen Levels After Radical Prostatectomy) . J Clin Oncol . 1999;17:1155–1163
  133. Petrylak DP . Chemotherapy for advanced hormone refractory prostate cancer . Urology . 1999;54:30–35
  134. Khan MA , Carducci MA , Partin AW . The evolving role of docetaxel in the management of androgen independent prostate cancer . J Urol . 2003;170:1709–1716
  135. Eisenberger MA , Blumenstein BA , Crawford ED , et al.   Bilateral orchiectomy with or without flutamide for metastatic prostate cancer . N Engl J Med . 1998;339:1036–1042
  136. Seckin B , Anthony CT , Murphy B , et al.   Can prostate-specific antigen be used as a valid end point to determine the efficacy of chemotherapy for advanced prostate cancer? . World J Urol . 1996;14(suppl 1):S26–S29
  137. Schneider JA , Divgi CR , Scott AM , et al.   Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer . J Nucl Med . 1994;35:1748–1752
  138. McNeil BJ . Value of bone scanning in neoplastic disease . Semin Nucl Med . 1984;14:277–286
  139. Oyama N , Akino H , Suzuki Y , et al.   FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation . Nucl Med Commun . 2001;22:963–969
  140. Oyama N , Kim J , Jones LA , et al.   MicroPET assessment of androgenic control of glucose and acetate uptake in the rat prostate and a prostate cancer tumor model . Nucl Med Biol . 2002;29:783–790
  141. Oyama N , Ponde DE , Dence C , et al.   Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation . J Nucl Med . 2004;45:519–525
  142. Shimizu N , Masuda H , Yamanaka H , et al.   Fluorodeoxyglucose positron emission tomography scan of prostate cancer bone metastases with flare reaction after endocrine therapy . J Urol . 1999;161:608–609
  143. Wong RJ , Lin DT , Schoder H , et al.   Diagnostic and prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography for recurrent head and neck squamous cell carcinoma . J Clin Oncol . 2002;20:4199–4208
  144. Vansteenkiste JF , Stroobants SG , Dupont PJ , et al.  Leuven Lung Cancer Group   Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer (An analysis of 125 cases) . J Clin Oncol . 1999;17:3201–3206
  145. Eary JF , OʼSullivan F , Powitan Y , et al.   Sarcoma tumor FDG uptake measured by PET and patient outcome (a retrospective analysis) . Eur J Nucl Med Mol Imaging . 2002;29:1149–1154
  146. Oyama N , Akino H , Suzuki Y , et al.   Prognostic value of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography imaging for patients with prostate cancer . Mol Imaging Biol . 2002;4:99–104
  147. Motzer RJ , Bander NH , Nanus DM . Renal-cell carcinoma . N Engl J Med . 1996;335:865–875
  148. Hilton S . Imaging of renal cell carcinoma . Semin Oncol . 2000;27:150–159
  149. Schreyer HH , Uggowitzer MM , Ruppert-Kohlmayr A . Helical CT of the urinary organs . Eur Radiol . 2002;12:575–591
  150. Kopka L , Fischer U , Zoeller G , et al.   Dual-phase helical CT of the kidney (Value of the corticomedullary and nephrographic phase for evaluation of renal lesions and preoperative staging of renal cell carcinoma) . AJR Am J Roentgenol . 1997;169:1573–1578
  151. Zagoria RJ , Bechtold RE , Dyer RB . Staging of renal adenocarcinoma (role of various imaging procedures) . Am J Roentgenol . 1995;164:363–370
  152. Margaritora S , Porziella V , DʼAndrilli A , et al.   Pulmonary metastases (can accurate radiological evaluation avoid thoracotomic approach?) . Eur J Cardiothorac Surg . 2002;21:1111–1114
  153. Diederich S , Semik M , Lentschig MG , et al.   Helical CT of pulmonary nodules in patients with extrathoracic malignancy (CT-surgical correlation) . Am J Roentgenol . 1999;172:353–360
  154. Wahl RL , Harney J , Hutchins G , et al.   Imaging of renal cancer using positron emission tomography with 2-deoxy-2-(18F)-fluoro-D-glucose (pilot animal and human studies) . J Urol . 1991;146:1470–1474
  155. Bachor R , Kotzerke J , Reske SN , et al.   [Lymph node staging of bladder neck carcinoma with positron emission tomography] . Urologe A . 1999;38:46–50
  156. Ramdave S , Thomas GW , Berlangieri SU , et al.   Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma . J Urol . 2001;166:825–830
  157. Kang DE , White RL , Zuger JH , et al.   Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma . J Urol . 2004;171:1806–1809
  158. Miyakita H , Tokunaga M , Onda H , et al.   Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer . Int J Urol . 2002;9:15–18
  159. Leibovich BC , Blute ML , Cheville JC , et al.   Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma (a stratification tool for prospective clinical trials) . Cancer . 2003;97:1663–1671
  160. Ficarra V , Righetti R , Pilloni S , et al.   Prognostic factors in patients with renal cell carcinoma (retrospective analysis of 675 cases) . Eur Urol . 2002;41:190–198
  161. Kavolius JP , Mastorakos DP , Pavlovich C , et al.   Resection of metastatic renal cell carcinoma . J Clin Oncol . 1998;16:2261–2266
  162. Raj GV , Partin AW , Polascik TJ . Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy . Cancer . 2002;94:987–996
  163. Jadvar H , Kherbache HM , Pinski JK , et al.   Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma . Clin Nephrol . 2003;60:395–400
  164. Safaei A , Figlin R , Hoh CK , et al.   The usefulness of F-18 deoxyglucose whole-body positron emission tomography (PET) for re-staging of renal cell cancer . Clin Nephrol . 2002;57:56–62
  165. Majhail NS , Urbain JL , Albani JM , et al.   F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma . J Clin Oncol . 2003;21:3995–4000
  166. Dalbagni G , Genega E , Hashibe M , et al.   Cystectomy for bladder cancer (a contemporary series) . J Urol . 2001;165:1111–1116
  167. Ghoneim MA , el-Mekresh MM , el-Baz MA , et al.   Radical cystectomy for carcinoma of the bladder (Critical evaluation of the results in 1,026 cases) . J Urol . 1997;158:393–399
  168. Stein JP , Lieskovsky G , Cote R , et al.   Radical cystectomy in the treatment of invasive bladder cancer (long-term results in 1,054 patients) . J Clin Oncol . 2001;19:666–675
  169. Frank I , Cheville JC , Blute ML , et al.   Transitional cell carcinoma of the urinary bladder with regional lymph node involvement treated by cystectomy (Clinicopathologic features associated with outcome) . Cancer . 2003;97:2425–2431
  170. Paik ML , Scolieri MJ , Brown SL , et al.   Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy . J Urol . 2000;163:1693–1696
  171. Yaman O , Baltaci S , Arikan N , et al.   Staging with computed tomography, transrectal ultrasonography and transurethral resection of bladder tumour (Comparison with final pathological stage in invasive bladder carcinoma) . Br J Urol . 1996;78:197–200
  172. Jager GJ , Barentsz JO , Oosterhof GO , et al.   Pelvic adenopathy in prostatic and urinary bladder carcinoma (MR imaging with a three-dimensional TI-weighted magnetization-prepared-rapid gradient-echo sequence) . AJR Am J Roentgenol . 1996;167:1503–1507
  173. Kim B , Semelka RC , Ascher SM , et al.   Bladder tumor staging (comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging) . Radiology . 1994;193:239–245
  174. de Jong IJ , Pruim J , Elsinga PH , et al.   Visualisation of bladder cancer using (11)C-choline PET (first clinical experience) . Eur J Nucl Med Mol Imaging . 2002;29:1283–1288
  175. Kosuda S , Kison PV , Greenough R , et al.   Preliminary assessment of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with bladder cancer . Eur J Nucl Med . 1997;24:615–620
  176. Schoder H , Erdi YE , Larson SM , et al.   PET/CT (A new imaging technology in nuclear medicine) . Eur J Nucl Med Mol Imaging . 2003;30:1419–1437
  177. Bar-Shalom R , Yefremov N , Guralnik L , et al.   Clinical performance of PET/CT in evaluation of cancer (additional value for diagnostic imaging and patient management) . J Nucl Med . 2003;44:1200–1209
  178. Ahlstrom H , Malmstrom PU , Letocha H , et al.   Positron emission tomography in the diagnosis and staging of urinary bladder cancer . Acta Radiol . 1996;37:180–185
  179. Deloar HM , Fujiwara T , Nakamura T , et al.   Estimation of internal absorbed dose of L-[methyl-11C]methionine using whole-body positron emission tomography . Eur J Nucl Med . 1998;25:629–633
  180. Seltzer MA , Jahan SA , Sparks R , et al.   Radiation dose estimates in humans for (11)C-acetate whole-body PET . J Nucl Med . 2004;45:1233–1236

PII: S0001-2998(04)00042-X

doi: 10.1053/j.semnuclmed.2004.06.004

Seminars in Nuclear Medicine
Volume 34, Issue 4 , Pages 274-292 , October 2004

Article Tools

* Image Usage & Resolution